STK11 and non-small cell lung carcinoma: Loss of STK11 function or mutations in LKB1 have been identified in 10%–20% of NSCLC and are believed to confer inferior survival outcomes and relative ICI resistance in advanced NSCLC when compared to wild-type tumours (117, 118).